Full Breakdown
Wireless Eye Implant Offers Hope for Blind Patients with AMD
3/9/2026, 7:45:18 AM
Overview of the PRIMA Retinal Implant
Recent clinical trials have demonstrated that a wireless retinal implant, known as the PRIMA implant, can help restore central vision in individuals suffering from advanced age-related macular degeneration (AMD). This condition, particularly in its atrophic form known as geographic atrophy (GA), is a leading cause of permanent blindness among older adults, affecting over 5 million people globally. The PRIMA implant, developed by Science Corporation, aims to replace damaged photoreceptors in the retina with a tiny electronic chip that converts light into electrical signals.
Clinical Trial Results
The PRIMAvera clinical trial involved 38 participants aged 60 and older across 17 medical centers in five European countries: France, Germany, Italy, the Netherlands, and the United Kingdom. Among the 32 participants who completed one year of follow-up, 26 (81%) reported significant improvements in visual acuity, with an average gain of 25 letters on a standard eye chart, equivalent to five lines of vision. Notably, 27 participants (84%) utilized the artificial vision provided by the implant in daily activities, such as reading numbers or short words.
Dr. José-Alain Sahel, co-leader of the trial and director of the UPMC Vision Institute, remarked, “It’s the first time that any attempt at vision restoration has achieved such results in a large number of patients.”
How the Implant Works
The PRIMA implant operates in conjunction with specialized glasses equipped with a small camera that captures images and transmits them to the implant using near-infrared light. The implant, positioned beneath the retina, stimulates surviving retinal neurons to send visual information to the brain. Users can adjust settings on the glasses to enhance readability. However, the implant requires daily use of the glasses to function, and the restored vision is limited to central detail, necessitating head movements to scan text or objects.
Surgical and Rehabilitation Considerations
The implantation procedure involves delicate retinal surgery, with 26 serious adverse events reported among 19 participants, primarily within the first two months post-surgery. Most complications were deemed related to the surgical process rather than the implant itself. Rehabilitation is crucial, as patients must learn to interpret the new visual signals, which can take time and commitment.
Regulatory Pathways and Future Research
Following the trial, Science Corporation has applied for CE mark approval in Europe and is exploring approval pathways with the U.S. Food and Drug Administration (FDA). Future studies will focus on the long-term stability of the visual signal and the impact of ongoing retinal degeneration on performance. Dr. Sahel noted, “While we can't yet restore full 20/20 vision with the implant alone, we are investigating methods that could further improve people's quality of life.”
Conclusion
The PRIMA retinal implant represents a significant advancement in the field of vision restoration for individuals with severe retinal diseases. While it does not fully replace natural sight, the device offers hope for improved quality of life through regained central vision, enabling patients to perform specific tasks like reading. Further research and regulatory approvals will be essential to expand access to this innovative technology.
